High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.

Blood
Peter DregerEuropean Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)

Abstract

High-risk chronic lymphocytic leukemia (CLL) has been defined by clinical and/or genetic resistance (TP53 abnormalities) to treatment with chemoimmunotherapy (CIT). With the availability of pathway inhibitors (PIs), such as kinase inhibitors and BCL2 antagonists, the outlook of CIT-resistant patients has dramatically improved. Here, we propose a revision of the concept of high-risk CLL, driven by TP53 abnormalities and response to treatment with PI. CLL high-risk-I, CIT-resistant is defined by clinically CIT-resistant disease with TP53 aberrations, but fully responsive to PI. This category is largely the domain of PI-based therapy, and cellular therapy (ie, allogeneic hematopoietic cell transplantation) remains an option only in selected patients with low individual procedure-related risk. In CLL high-risk-II, CIT- and PI-resistant, characterized by increasing exhaustion of pharmacological treatment possibilities, cellular therapies (including chimeric antigen receptor-engineered T cells) should be considered in patients eligible for these procedures. Moreover, molecular and cellular therapies are not mutually exclusive and could be used synergistically to exploit their full potential.

References

Sep 13, 1990·The New England Journal of Medicine·G JuliussonG Gahrton
Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Jun 11, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel WeisdorfJohn Klein
Sep 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorDavid G Maloney
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
May 30, 2014·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd
Oct 11, 2014·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Apr 8, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Uri RozovskiZeev Estrov
Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Dec 8, 2015·The New England Journal of Medicine·John C ByrdRichard R Furman
Oct 28, 2016·British Journal of Haematology·Philip A ThompsonFlorence Cymbalista
Oct 18, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohamed A Kharfan-DabajaBipin N Savani
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Preetesh JainJan A Burger
Nov 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J ChowK Scott Baker

❮ Previous
Next ❯

Citations

Dec 7, 2018·Hematology·Jennifer R Brown
Apr 11, 2019·Expert Opinion on Drug Metabolism & Toxicology·Anna Korycka-WolowiecTadeusz Robak
May 3, 2019·Current Hematologic Malignancy Reports·Adam S KittaiAlexey V Danilov
Nov 26, 2019·The Cancer Journal·Adam S Kittai, Jennifer A Woyach
Jan 25, 2020·Annual Review of Pathology·Ferran NadeuElías Campo
Nov 28, 2019·Expert Review of Hematology·Riccardo MoiaGianluca Gaidano
Nov 5, 2019·Frontiers in Immunology·Seila Lorenzo-HerreroAlejandro López-Soto
Sep 27, 2019·Frontiers in Oncology·Ilaria Del GiudiceRobin Foà
Apr 7, 2019·Bone Marrow Transplantation·Rafael F DuarteUNKNOWN European Society for Blood and Marrow Transplantation (EBMT)
Nov 15, 2019·HemaSphere·Deyan Y YosifovDaniel Mertens
Dec 7, 2019·Hematology·Barbara EichhorstMichael Hallek
Mar 15, 2020·Current Treatment Options in Oncology·Lorenzo Iovino, Mazyar Shadman
Oct 8, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Inhye E AhnAdrian Wiestner
Oct 14, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephan Stilgenbauer
Dec 5, 2020·Hematology·Lindsey E Roeker, Anthony R Mato
Nov 16, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Suman PaulDouglas E Gladstone
Oct 23, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EichhorstUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
May 1, 2021·Expert Opinion on Investigational Drugs·Stefano MolicaAaron Polliack
Jun 3, 2021·International Journal of Molecular Sciences·Veronika Mancikova, Michal Smida
Jun 28, 2021·Hematology/oncology Clinics of North America·Mazyar Shadman, David G Maloney
Aug 17, 2021·The Cancer Journal·Peter Dreger
Sep 4, 2021·Blood Advances·Thomas E LewMary Ann Anderson

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.